2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Profiling, Treatment Considerations, Drug Development, Drug-Drug Interactions, Supportive Care, Biological Therapies, Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Adverse Events, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Practice Models, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Immunology, Autoimmune Hemolytic Anemia, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, ALL, Aggressive Lymphoma, Research, Fundamental Science, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pregnant
PAPER

1337 Thrombosis complications in a retrospective cohort of trinetx adult patients withmultiple myeloma who received bispecific antibodies

Shreyas Shirodkar, MD, Jennifer Elizabeth Collins, PhD2, Amir Kamran, MD3
1 Charleston Area Medical Center, Charleston, West Virginia, United States
2 Charleston Area Medical Center, Charleston, West Virginia, United States
3 Charleston Area Medical Center, Charleston, West Virginia, United States

Background: Multiple myeloma (MM) carries a high thrombotic risk driven by disease- and treatment-related factors, with venous thromboembolism (VTE) rates ranging from 26% to 67% depending on treatment line and prophylaxis use. T-cell-redirecting bispecific antibodies (teclistamab, elranatamab, talquetamab, linvoseltamab) are now FDA-approved for relapsed/refractory MM and achieve overall response rates of 61%-72% in heavily pretreated disease, but are associated with cytokine release syndrome (CRS) in 58%-77% of patients. CRS-associated cytokines, including IL-6, IL-1β, TNF-α, and IFN-γ, converge on the coagulation cascade through multiple mechanisms, and real-world data suggest higher VTE incidence with related T-cell-engaging therapies such as CAR-T. In contrast, daratumumab-containing regimens have been associated with a lower VTE risk relative to non-daratumumab regimens. Whether bispecific antibody exposure alters thrombotic and bleeding risk relative to daratumumab alone has not been well characterized. Herein, we compare the risk of venous and arterial thromboembolism, major bleeding, anticoagulation initiation, and hospitalization between MM patients receiving bispecific antibodies plus daratumumab and those receiving daratumumab alone.

Methods: Using the TriNetX national electronic health record database, MM patients who received a bispecific antibody within 1 year of daratumumab use were compared with those who did not. Patients were 1:1 propensity-score matched on age, sex, race, ethnicity, smoking history, comorbidities, prior anticoagulant use, prior aspirin use, prior corticosteroid use, prior autologous stem cell transplantation, and prior pomalidomide, bortezomib, and carfilzomib use. A 366-day landmark following daratumumab initiation was applied to both cohorts to minimize immortal time bias and crossover from baseline events. Primary outcomes were 90-day and 1-year incidence of deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial thromboembolism (ATE); secondary outcomes were major bleeding, anticoagulation initiation, and all-cause hospitalization. Outcomes were evaluated using Kaplan-Meier analysis with log-rank testing.

Results: Of 274 patients who received a bispecific antibody within 1 year of daratumumab and 18,316 who did not, 273 patients remained in each group after matching. ATE was too rare to analyze despite expansion of the composite outcome definition. Anticoagulant initiation was significantly higher in the bispecific antibody group (HR = 1.83, 95% CI: 1.36-2.45), as was risk of DVT (HR = 2.16, 95% CI: 1.04-4.48). PE was too rare to analyze independently; a composite VTE outcome (DVT + PE) showed a trend toward higher risk with bispecific antibody exposure that did not reach statistical significance (HR = 1.87, 95% CI: 0.97-3.58). Major bleeding was also more common in the bispecific antibody group but this difference was not significant (HR = 1.75, 95% CI: 0.78-3.91). Hospitalization was significantly more common in the bispecific antibody group (HR = 1.72, 95% CI: 1.11-2.66).

Conclusion: In this real-world, propensity-matched cohort, MM patients receiving bispecific antibodies in addition to daratumumab had significantly higher rates of DVT, anticoagulant initiation, and hospitalization compared with those receiving daratumumab alone, with a similar trend for composite VTE and major bleeding that did not reach statistical significance, likely reflecting limited event numbers. These findings suggest bispecific antibody therapy may associated with an increased thrombotic risk in MM beyond that conferred by daratumumab alone, supporting further prospective evaluation of thromboprophylaxis strategies and closer monitoring as use of this drug class expands.

Shreyas Shirodkar, MD: No relevant conflicts of interest to declare.